Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials

Mack Roach, Jiandong Lu, Miljenko V. Pilepich, Sucha O. Asbell, Mohammed Mohuidden, Roger Terry, David Grignon

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Purpose: Gleason score (GS), T stage, and pathologic lymph node status have been described as major independent predictors of death due to prostate cancer in men treated with external beam radiotherapy (XRT). In this analysis we combine these three factors to define prognostic subgroups that correlate with disease-specific survival (DSS) death from prostate cancer. Methods and Materials: Men entered on one of four Radiation Therapy Oncology Group (RTOG) Phase III randomized trials between 1975 and 1992, for clinically localized prostate cancer (CAP) (n = 1557), were selected for this analysis. Patients were included if: 1) they were evaluable, and eligible for the trial; 2) they received no hormonal therapy with their initial treatment; and 3) follow-up was available. For this study a DSS event was declared if: 1) death was certified as due to CAP; 2) death was due to complications of treatment; or 3) death was from unknown causes with active malignancy. The median follow-up for patients treated on early and late RTOG studies exceeded 11 and 6 years respectively. Subgroups were identified based on their pretreatment GS, T- stage, and lymph node such that patients with similar risk of dying from prostate cancer were combined. Results: By combining patients with similar DSS, four subgroups were identified. Risk Group 1 patients had a GS = 2-6, and T1-2Nx; Group 2: GS = 2-6, T3Nx; or GS = 2-6, N+, or GS = 7, T1-2Nx; Group 3: T3Nx, GS = 7; or N+, GS = 7, or T1-2Nx, GS = 8-10; and Group 4 patients were T3Nx, GS = 8-10, or N+, GS = 8-10. The 5-, 10-, and 15-year DSS was 96%, 86%, and 72%; 94%, 75%, and 61%; 83%, 62%, and 39%; and 64%, 34%, and 27% for Groups 1 through 4, respectively. Conclusions: Recognition of these four risk groups provides a basis for estimating the long-term DSS for men treated with XRT alone and should facilitate the design of future prospective randomized trials. (C) 2000 Elsevier Science Inc.

Original languageEnglish (US)
Pages (from-to)609-615
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume47
Issue number3
DOIs
StatePublished - Jun 1 2000
Externally publishedYes

Fingerprint

Radiation Oncology
Neoplasm Grading
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Clinical Trials
death
Survival
subgroups
lymphatic system
Lymph Nodes
pretreatment
therapy
estimating
Therapeutics
causes
predictions

Keywords

  • Long-term survival
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. / Roach, Mack; Lu, Jiandong; Pilepich, Miljenko V.; Asbell, Sucha O.; Mohuidden, Mohammed; Terry, Roger; Grignon, David.

In: International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 3, 01.06.2000, p. 609-615.

Research output: Contribution to journalArticle

Roach, Mack ; Lu, Jiandong ; Pilepich, Miljenko V. ; Asbell, Sucha O. ; Mohuidden, Mohammed ; Terry, Roger ; Grignon, David. / Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials. In: International Journal of Radiation Oncology Biology Physics. 2000 ; Vol. 47, No. 3. pp. 609-615.
@article{85dc3f7c3e314c9f8ec7ccdd3f5102a1,
title = "Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials",
abstract = "Purpose: Gleason score (GS), T stage, and pathologic lymph node status have been described as major independent predictors of death due to prostate cancer in men treated with external beam radiotherapy (XRT). In this analysis we combine these three factors to define prognostic subgroups that correlate with disease-specific survival (DSS) death from prostate cancer. Methods and Materials: Men entered on one of four Radiation Therapy Oncology Group (RTOG) Phase III randomized trials between 1975 and 1992, for clinically localized prostate cancer (CAP) (n = 1557), were selected for this analysis. Patients were included if: 1) they were evaluable, and eligible for the trial; 2) they received no hormonal therapy with their initial treatment; and 3) follow-up was available. For this study a DSS event was declared if: 1) death was certified as due to CAP; 2) death was due to complications of treatment; or 3) death was from unknown causes with active malignancy. The median follow-up for patients treated on early and late RTOG studies exceeded 11 and 6 years respectively. Subgroups were identified based on their pretreatment GS, T- stage, and lymph node such that patients with similar risk of dying from prostate cancer were combined. Results: By combining patients with similar DSS, four subgroups were identified. Risk Group 1 patients had a GS = 2-6, and T1-2Nx; Group 2: GS = 2-6, T3Nx; or GS = 2-6, N+, or GS = 7, T1-2Nx; Group 3: T3Nx, GS = 7; or N+, GS = 7, or T1-2Nx, GS = 8-10; and Group 4 patients were T3Nx, GS = 8-10, or N+, GS = 8-10. The 5-, 10-, and 15-year DSS was 96{\%}, 86{\%}, and 72{\%}; 94{\%}, 75{\%}, and 61{\%}; 83{\%}, 62{\%}, and 39{\%}; and 64{\%}, 34{\%}, and 27{\%} for Groups 1 through 4, respectively. Conclusions: Recognition of these four risk groups provides a basis for estimating the long-term DSS for men treated with XRT alone and should facilitate the design of future prospective randomized trials. (C) 2000 Elsevier Science Inc.",
keywords = "Long-term survival, Prostate cancer, Radiotherapy",
author = "Mack Roach and Jiandong Lu and Pilepich, {Miljenko V.} and Asbell, {Sucha O.} and Mohammed Mohuidden and Roger Terry and David Grignon",
year = "2000",
month = "6",
day = "1",
doi = "10.1016/S0360-3016(00)00578-2",
language = "English (US)",
volume = "47",
pages = "609--615",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on radiation therapy oncology group clinical trials

AU - Roach, Mack

AU - Lu, Jiandong

AU - Pilepich, Miljenko V.

AU - Asbell, Sucha O.

AU - Mohuidden, Mohammed

AU - Terry, Roger

AU - Grignon, David

PY - 2000/6/1

Y1 - 2000/6/1

N2 - Purpose: Gleason score (GS), T stage, and pathologic lymph node status have been described as major independent predictors of death due to prostate cancer in men treated with external beam radiotherapy (XRT). In this analysis we combine these three factors to define prognostic subgroups that correlate with disease-specific survival (DSS) death from prostate cancer. Methods and Materials: Men entered on one of four Radiation Therapy Oncology Group (RTOG) Phase III randomized trials between 1975 and 1992, for clinically localized prostate cancer (CAP) (n = 1557), were selected for this analysis. Patients were included if: 1) they were evaluable, and eligible for the trial; 2) they received no hormonal therapy with their initial treatment; and 3) follow-up was available. For this study a DSS event was declared if: 1) death was certified as due to CAP; 2) death was due to complications of treatment; or 3) death was from unknown causes with active malignancy. The median follow-up for patients treated on early and late RTOG studies exceeded 11 and 6 years respectively. Subgroups were identified based on their pretreatment GS, T- stage, and lymph node such that patients with similar risk of dying from prostate cancer were combined. Results: By combining patients with similar DSS, four subgroups were identified. Risk Group 1 patients had a GS = 2-6, and T1-2Nx; Group 2: GS = 2-6, T3Nx; or GS = 2-6, N+, or GS = 7, T1-2Nx; Group 3: T3Nx, GS = 7; or N+, GS = 7, or T1-2Nx, GS = 8-10; and Group 4 patients were T3Nx, GS = 8-10, or N+, GS = 8-10. The 5-, 10-, and 15-year DSS was 96%, 86%, and 72%; 94%, 75%, and 61%; 83%, 62%, and 39%; and 64%, 34%, and 27% for Groups 1 through 4, respectively. Conclusions: Recognition of these four risk groups provides a basis for estimating the long-term DSS for men treated with XRT alone and should facilitate the design of future prospective randomized trials. (C) 2000 Elsevier Science Inc.

AB - Purpose: Gleason score (GS), T stage, and pathologic lymph node status have been described as major independent predictors of death due to prostate cancer in men treated with external beam radiotherapy (XRT). In this analysis we combine these three factors to define prognostic subgroups that correlate with disease-specific survival (DSS) death from prostate cancer. Methods and Materials: Men entered on one of four Radiation Therapy Oncology Group (RTOG) Phase III randomized trials between 1975 and 1992, for clinically localized prostate cancer (CAP) (n = 1557), were selected for this analysis. Patients were included if: 1) they were evaluable, and eligible for the trial; 2) they received no hormonal therapy with their initial treatment; and 3) follow-up was available. For this study a DSS event was declared if: 1) death was certified as due to CAP; 2) death was due to complications of treatment; or 3) death was from unknown causes with active malignancy. The median follow-up for patients treated on early and late RTOG studies exceeded 11 and 6 years respectively. Subgroups were identified based on their pretreatment GS, T- stage, and lymph node such that patients with similar risk of dying from prostate cancer were combined. Results: By combining patients with similar DSS, four subgroups were identified. Risk Group 1 patients had a GS = 2-6, and T1-2Nx; Group 2: GS = 2-6, T3Nx; or GS = 2-6, N+, or GS = 7, T1-2Nx; Group 3: T3Nx, GS = 7; or N+, GS = 7, or T1-2Nx, GS = 8-10; and Group 4 patients were T3Nx, GS = 8-10, or N+, GS = 8-10. The 5-, 10-, and 15-year DSS was 96%, 86%, and 72%; 94%, 75%, and 61%; 83%, 62%, and 39%; and 64%, 34%, and 27% for Groups 1 through 4, respectively. Conclusions: Recognition of these four risk groups provides a basis for estimating the long-term DSS for men treated with XRT alone and should facilitate the design of future prospective randomized trials. (C) 2000 Elsevier Science Inc.

KW - Long-term survival

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0034212312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034212312&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(00)00578-2

DO - 10.1016/S0360-3016(00)00578-2

M3 - Article

VL - 47

SP - 609

EP - 615

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -